Semaglutide Trial Investigates Hyperglycemia After Kidney Transplantation

Post-transplant hyperglycemia is a frequent and serious complication occurring in renal transplant recipients, often within the first two weeks post-surgery. Current standard-of-care primarily relies on insulin treatment, which carries inherent risks such as hypoglycemia (dangerously low blood sugar) and undesirable weight gain. This Phase 4 clinical trial aims to address the critical knowledge gap by evaluating the safety and efficacy of oral semaglutide as a potentially superior alternative for managing hyperglycemia in this vulnerable patient population.

As an ongoing, recruiting study, specific efficacy and safety data are not yet available. However, the trial is designed to rigorously evaluate the impact of oral semaglutide on glycemic control in renal transplant recipients. The primary endpoint will assess the change in HbA1c (a measure of average blood sugar over 2-3 months) from baseline, aiming to demonstrate a significant reduction in the semaglutide group compared to placebo. The trial is powered to detect a clinically meaningful difference in glycemic parameters, with an anticipated superiority of oral semaglutide over placebo in managing post-transplant hyperglycemia. Secondary endpoints will include changes in fasting plasma glucose, body weight, and the incidence of hypoglycemic events, where semaglutide is expected to show a favorable profile with potentially lower rates of hypoglycemia and beneficial effects on weight. Safety and tolerability, including adverse events, will also be meticulously monitored to ensure the drug's suitability for this patient population.